COMPANY

Immunicom

HQ: San Diego, CA source · immunicom.com ↗ · West Coast

Keywords: oncology Advanced Breast Cancer Non Small Cell Lung Cancer LW-02 device immunopheresis combined with atezolizumab LW-02 device immunopheresis combined with weekly paclitaxel LW-02 device immunopheresis

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)1NIH grants

Timeline

Oct 1, 2020 Trial start Phase 2: Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). source ↗
May 31, 2019 Trial start Phase 1/Phase 2: A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04004910	A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	May 31, 2019	Dec 31, 2022 (estimated)
NCT04690686	Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).	Phase 2	Unknown status (ClinicalTrials.gov)	Oct 1, 2020	Aug 31, 2022 (estimated)

NIH awards 1

Annual award amounts. Total $1.1M.

Jun 8, 2022 NIH award 1R44CA261565-01A1 FY2022: $1,072,330 awarded for that fiscal year; activity R44 (SBIR); PI SHENOUDA, CHRISTIAN; recipient as written: IMMUNICOM, INC., SAN DIEGO, CA. Evaluation of Subtractive Immunopheresis source ↗